DrugBank 5.0: a major update to the DrugBank database for 2018

David S. Wishart(University of Alberta), Yannick Djoumbou-Feunang(University of Alberta), An Chi Guo(University of Alberta), Elvis Lo(University of Alberta), Ana Marcu(University of Alberta), Jason R. Grant(University of Alberta), Tanvir Sajed(University of Alberta), Daniel L. Johnson(University of Alberta), Carin Li(University of Alberta), Zinat Sayeeda(University of Alberta), Nazanin Assempour(University of Alberta), Ithayavani Iynkkaran(University of Alberta), Yifeng Liu(University of Alberta), Adam Maciejewski(University of Alberta), Nicola Gale, Alexander E. Wilson, Lucy Chin, Ryan Cummings, Diana Le, Allison Pon(University of Alberta), Craig Knox(University of Alberta), Michael Wilson(University of Alberta)
Nucleic Acids Research
November 4, 2017
Cited by 8,741Open Access
Full Text

Abstract

DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.


Related Papers